Jan 07,2009
Visanne® - new long-term treatment for endometriosis submitted for registration in Europe
Berlin, January 7, 2009 – Bayer Schering Pharma AG, Germany, has submitted Visanne® for the treatment of endometriosis for registration to all Member States of the European Community. The Netherlands will serve as the Reference Member State for the Decentralized Procedure to receive European-wide Marketing Authorization. Visanne contains 2 mg of Dienogest and is administered orally once a day. In contrast to other drugs used for the treatment of this chronic gynecological disease, Visanne is an endometriosis-specific therapy for the long-term treatment of endometriosis. The current standard-therapy with GnRH analogue is only suitable for short-term treatment due to severe side-effects. » more